The KRAS oncogene is mutated in approximately 35%-45% of colorectal cancers, and KRAS mutational status testing has been highlighted in recent years. The most frequent mutations in this gene, point substitutions in codons 12 and 13, were validated as negative predictors of response to anti-...
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021). Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology. Cells, 10(3), 667. https://doi.org/10.3390/cells10030667 Li, S., Balmain, A., & Counter,...
KRAS mutation is responsible for 40–50% of colorectal cancers (CRCs). RNA-seq data and bioinformatics methods were used to analyze the transcriptional profiles of KRAS mutant (mtKRAS) in comparison with the wild-type (wtKRAS) cell lines, followed by in-
FULL PAPER British Journal of Cancer (2013) 108, 1757–1764 | doi: 10.1038/bjc.2013.118 Keywords: colorectal cancer; KRAS; survival; mortality; microsatellite instability; BRAF KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers A I Phipps*...
TheRASgene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms,KRASis the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a...
Consecutive and automatic detection of multi-gene mutations from colorectal cancer samples by coupling droplet array-based capillary electrophoresis and PC... The efficacy of targeted therapy is associated with multi-gene mutation status. Carrying out effective multi-genotyping analysis in combination has ...
Approximately 30% to 50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene, indicating that up to 50% of patients with colorectal cancer (CRC) might respond to anti-epidermal growth factor receptor (EGFR) antibody therapy. However, 40
Demographic trends and KRAS/BRAFV600E mutations in colorectal cancer patients of South China: A single‐site reportdoi:10.1002/ijc.31973KRAS mutationBRAF mutationtubular adenocarcinomademographic trendscolorectal cancerThe incidence of colorectal cancer (CRC) is increasing in China. Here, we aimed to ...
Recent retrospective evidence from several randomized studies has established that advanced colorectal cancer patients with tumors harboring a mutation in the KRAS gene do not derive benefit from the administration of epidermal growth factor receptor-directed monoclonal antibodies, such as cetuximab or panitu...
Sporadic colorectal cancers with microsatellite instability (MSI) frequently contain a mutation of the BRAF gene. Additionally, it has been shown that BRAF mutations in colorectal cancers are mutually exclusive of KRAS mutation. We evaluated 14 cases of colorectal cancer with MSI that were BRAF wild...